Gallbladder removal surgeries spiked 15% last year, and surgeons suspect weight-loss injections bear responsibility.
Drugs like semaglutide and tirzepatide trigger rapid weight loss by slowing stomach emptying and reducing appetite. This mechanism creates ideal conditions for gallstone formation. When the gallbladder doesn't contract regularly, cholesterol-rich bile pools and hardens into stones. Patients on these medications experience accelerated weight loss, compressing this stone-formation timeline.
The uptick in procedures reflects real clinical consequences. Surgeons report more emergency gallbladder removals among patients taking GLP-1 receptor agonists, the class of drugs behind Ozempic, Wegovy, and Mounjaro.
Researchers emphasize the need for controlled studies tracking gallstone incidence in weight-loss medication users versus other weight-loss methods. Current evidence remains largely observational. Some gallstone development occurs naturally during any rapid weight loss, making it difficult to isolate the medication's specific contribution.
The pharmaceutical companies marketing these drugs haven't provided comprehensive data on gallbladder complications. Healthcare providers now monitor patients on these medications for abdominal pain, nausea, and other gallstone warning signs.
Patients shouldn't stop their medications without medical guidance. Instead, doctors should discuss gallbladder risk during initial consultations and watch for symptoms requiring surgical intervention.